Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010.
Euro Surveill
; 15(18)2010 May 06.
Article
en En
| MEDLINE
| ID: mdl-20460094
ABSTRACT
During the 2009 influenza pandemic, a monovalent AS03-adjuvanted vaccine was almost exclusively used in Germany for immunisation against the 2009 pandemic influenza A(H1N1) virus. One-dose vaccination was recommended for all age groups. We applied the screening method for the rapid assessment of vaccine effectiveness (VE) based on reported data of vaccinated and unvaccinated pandemic influenza cases and vaccination coverage estimates. Preliminary results demonstrate excellent VE in persons aged 14-59 years (96.8%; 95% confidence interval (CI) 95.2-97.9) and moderately high VE in those 60 years or older (83.3%; 95% CI 71.0-90.5).
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Vacunas contra la Influenza
/
Gripe Humana
/
Subtipo H1N1 del Virus de la Influenza A
Tipo de estudio:
Qualitative_research
Límite:
Adolescent
/
Adult
/
Humans
/
Middle aged
País/Región como asunto:
Europa
Idioma:
En
Revista:
Euro Surveill
Asunto de la revista:
DOENCAS TRANSMISSIVEIS
Año:
2010
Tipo del documento:
Article
País de afiliación:
Alemania